Creative Destruction of Venture Capital: DAOs, Longevity, A Role for Pharma? with Michael Baran From Pfizer Ventures

https://is1-ssl.mzstatic.com/image/thumb/Podcasts126/v4/21/3b/be/213bbe66-7a8c-3a5d-7011-96f9be64b323/mza_1747005262675932524.jpg/600x600bb.jpg

VitaDAO is a community owned collective funding early stage longevity research, governed by $VITA

VitaDAO

35 episodes

1 day ago

Our core mission is the acceleration of research and development (R&D) in the longevity space and the extension of human life and healthspan. To achieve this, VitaDAO collectively funds and digitizes research in the form of IP-NFTs. 👉vitadao.com

Technology

RSS

All content for VitaDAO is a community owned collective funding early stage longevity research, governed by $VITA is the property of VitaDAO and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Technology

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/15308511/15308511-1638803549740-47bc81d2de916.jpg

Creative Destruction of Venture Capital: DAOs, Longevity, A Role for Pharma? with Michael Baran From Pfizer Ventures

VitaDAO is a community owned collective funding early stage longevity research, governed by $VITA

25 minutes 8 seconds

2 years ago

Creative Destruction of Venture Capital: DAOs, Longevity, A Role for Pharma? with Michael Baran From Pfizer Ventures

Michael Baran, MBA, Ph.D. is Executive Director, WRDM, and Partner at Pfizer Ventures. Mike is responsible for identifying, evaluating, making, and managing equity investments aligned with the future directions of Pfizer.

This talk is part of the 2nd VitaDAO Crypto meets Longevity Symposium!

00:00 Intro
01:47 Creative destruction of Venture Capital
02:20 The trend toward Decentralization
05:29 The future of VC will be Decentralized
08:56 DeSci gaining recognition in mainstream scientific forums
10:01 Pfizer focus
13:19 2021 Longevity clinical trials
15:57 Longevity dealflow
18:05 DeSci: The path to 2030 & beyond
21:15 Q&A